`
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`______________
`
`
`APPLE INC.,
`Petitioner,
`
`v.
`
`OMNI MEDSCI, INC.,
`Patent Owner.
`
`______________
`
`
`U.S. Patent No. 10,188,299
`
`IPR Case No.: IPR2020-00175
`
`
`______________
`
`
`
`
`PATENT OWNER’S SUR-REPLY REGARDING 35 U.S.C. § 325(d)
`
`
`
`
`
`
`
`
`
`Case No.: IPR2020-00175
`Patent No.: 10,188,299
`
`
`I.
`
`Introduction
`
`Atty. Dkt. No.: OMSC0117IPR1
`
`The examiner who allowed the ‘299 patent (four times) specifically considered
`
`the Lisogurski/Carlson references (twice) and Apple’s Invalidity Contentions and
`
`Claim Charts (“Charts”), which detail the arguments Apple now advances. The ‘299
`
`claims differ materially from the “family members” (other than the ‘533) that Apple
`
`mentions in its Introduction, the most germane difference being the “pulse rate”
`
`limitation. The ‘299 “pulse rate” limitation reads, in pertinent part:
`
`the light source configured to increase the [SNR] ... by increasing a
`
`pulse rate of at least one of the plurality of semiconductor sources....
`
`Lisogurski and Carlson do not disclose or suggest the “pulse rate” limitation. At
`
`a minimum, “reasonable minds can disagree regarding the purported treatment of the
`
`art or arguments,” so “it cannot be said that the Office erred in a manner material to
`
`patentability.” Advanced Bionics, LLC v. Med-El Elektromedizinische Geräte GmbH,
`
`IPR2019-01469, Paper 6 at 9 (PTAB 2/13/20) (designated precedential 3/24/20).
`
`II. Apple has failed in its burden to show the Examiner erred
`
`The “pulse rate” limitation is the same limitation in claim 5 of the ‘533 patent,
`
`which Apple challenged in its district court Invalidity Contentions and Charts. Apple
`
`cited Lisogurski (Ex. 2126, pp. 7-9) and Carlson (Ex. 2127, pp. 4-5), “the same prior
`
`art” relied on in the Petition. 35 U.S.C. § 325(d).
`
`The Examiner expressly considered (1) Lisogurski and Carlson, twice, (Ex.
`
`1
`
`
`
`Case No.: IPR2020-00175
`Patent No.: 10,188,299
`
`
`1002, p. 522, item 7 and p. 523, item 1; p. 588, item 27 and p. 589, item 1), and (2)
`
`Atty. Dkt. No.: OMSC0117IPR1
`
`Apple’s Carlson and Lisogurski Charts (Ex. 1002, p. 591, item 14 and p. 592, item 16).
`
`Apple’s Charts “identify[] specifically where and how in each alleged item of prior art
`
`each limitation of each asserted claim is found.” (N. Dist. Cal. Patent L.R. 3-1(c),
`
`available at www.cand.uscourts.gov/rules/patent-local-rules.) In the Petition, Apple
`
`cites Lisogurski/Carlson passages identical to those cited in the Charts, i.e., the
`
`examiner had Apple’s “pulse rate” assertions. (Compare Pet. at 48-50 with Ex. 2126,
`
`pp. 7-9 and Pet. 50-51 with Ex. 2127, pp. 4-5.)
`
`Because Patent Owner used the QPIDS program,1 the examiner’s only task was
`
`
`1 The QPIDS program allows an “IDS to be considered by the examiner” after a notice
`
`of allowance. www.uspto.gov/patent/initiatives/quick-path-information-disclosure-
`
`statement-qpids. “Where the examiner determines that no item of information in the
`
`IDS necessitates reopening prosecution, the USPTO will issue a corrected notice of
`
`allowability.” Id.
`
`
`
`Apple calls Patent Owner’s QPIDS submission of Apple’s contentions and
`
`Charts a “dump[] [of] over 90 documents.” (Reply at 4.) If it was a “dump,” it was only
`
`because Apple “dumped” those same documents on Patent Owner in the lawsuit,
`
`obliging Patent Owner to disclose Apple’s “dump” to the examiner.
`
`2
`
`
`
`Case No.: IPR2020-00175
`Patent No.: 10,188,299
`
`
`to review the Charts and references and determine if Apple’s arguments made the claims
`
`Atty. Dkt. No.: OMSC0117IPR1
`
`unpatentable. These facts satisfy the Becton, Dickinson factors: (a) & (b) the asserted
`
`art and prior art involved during examination are identical; (c) Apple’s Invalidity
`
`Contentions and Charts were the only things the examiner considered before issuing his
`
`third notice of allowance; (d) substantial overlap exists between the arguments made
`
`during examination and the manner in which the Petition relies on the prior art; (e)
`
`Apple fails to show how the examiner erred in its evaluation of the asserted prior art;
`
`and (f) the substantially similar evidence and facts in the Petition do not warrant
`
`reconsideration of the prior art or arguments. Advanced Bionics, p. 9, n. 10.
`
`Apple’s Reply does not properly evaluate the Becton, Dickinson factors as
`
`required by Advanced Bionics. When the same art is presented to the Office—which
`
`occurred here—that satisfies factors (a), (b), and (d). Advanced Bionics, pp. 10, 20. For
`
`factor (c), Apple asserts that the examiner’s review was “cursory,” but offers no
`
`evidence to support that claim. (Reply at 3.)
`
`For factors (e) and (f), Apple offers conclusions, without supporting evidence.
`
`Apple relies on the Board’s institution for the ‘546 patent—which lacks the “pulse rate”
`
`limitation—and asserts, without analysis, the Board should do the same here. (Reply at
`
`4.) Then Apple lists several types of evidence (id., pp. 4-5) without analyzing how they
`
`“show the Office erred by overlooking something persuasive under factors (e) and (f).”
`
`Advanced Bionics, p. 10. Apple fails to “demonstrate that the Examiner erred in the
`
`3
`
`
`
`Case No.: IPR2020-00175
`Patent No.: 10,188,299
`
`
`evaluation of the prior art, for example, by showing that the Examiner misapprehended
`
`Atty. Dkt. No.: OMSC0117IPR1
`
`or overlooked specific teachings in the relevant prior art. . . .” Id., p. 21.
`
`III. At best for Apple, reasonable minds can disagree
`
`In its IPR2019-00916 institution decision (“‘533 ID”), the Board stated,
`
`“Petitioner has failed to sufficiently demonstrate how Lisogurski teaches increasing
`
`LED firing rate to increase signal-to-noise.” (Ex. 2124, p. 30.) So, at best for Apple,
`
`reasonable minds can disagree about whether Lisogurski discloses the “pulse rate”
`
`limitation.
`
`As for Carlson, the Petition and the Charts cite the same paragraphs of Carlson
`
`for the “pulse rate” limitation ([0067]-[0069]). (Compare Pet., pp. 50-51 with Ex. 2127,
`
`pp. 4-5.) Thus, the examiner had the same contentions Apple presents to the Board.
`
`Carlson teaches that modulated light at a “chosen” frequency F0 (Fig. 8) is an
`
`alternative to continuous light (Fig. 7c). (Ex. 1009, [0069], emphasis added.) Carlson
`
`never discloses a device that increases the modulation frequency or pulse rate from an
`
`initial rate. (Ex. 2122, MacFarlane Decl., ¶ 79.)
`
`Apple’s expert, Dr. Anthony, does not advance an obviousness analysis other
`
`than modifying Lisogurski using the “Carlson technique.” If a person of ordinary skill
`
`in the art were to apply the “Carlson technique” to Lisogurski, the result would simply
`
`be a pulse oximeter having a “chosen” firing rate above 1000Hz. (Ex. 2122, MacFarlane
`
`Decl., ¶ 81.) Because neither reference teaches improving SNR by increasing an initial
`
`4
`
`
`
`Case No.: IPR2020-00175
`Patent No.: 10,188,299
`
`
`pulse rate, the references, alone or combined, do not make the ‘299 claims prima facie
`
`Atty. Dkt. No.: OMSC0117IPR1
`
`obvious.
`
`On page 2, Apple relies on the Board’s preliminary views in the ‘533 ID but those
`
`preliminary views are not evidence. And the Board there did not have Dr. MacFarlane’s
`
`declaration,2 of record here, which shows that reasonable minds can disagree.
`
`IV. Conclusion
`
`Because reasonable minds can disagree, and because Apple has not met its
`
`burden to show that the examiner erred, the Board should deny institution so the district
`
`court case may proceed.3
`
`Dated: May 28, 2020
`
`
`
`
`
`Respectfully submitted,
`/Thomas A. Lewry/
`
`
`
`
`
`
`2 Apple wrongly states the Board weighed “evidence from both parties,” Reply at 2, but
`
`the Board did not have Dr. MacFarlane’s declaration when it issued the ‘533 ID.
`
`3 Apple wrongly claims, “the litigation involving the ‘299 patent is stayed for reasons
`
`unrelated to IPRs.” (Paper 8 at 5.) The district court only stayed the case “until final
`
`resolution, including appeals, of all inter partes review Proceedings in which the
`
`asserted patents are at issue.” Omni MedSci, Inc. v. Apple Inc., Case No. 4:19cv5673,
`
`Dkt. #219, p. 2. Once this IPR is concluded, the lawsuit can proceed because all other
`
`IPRs involving the asserted patents have been resolved.
`
`5
`
`
`
`Case No.: IPR2020-00175
`Patent No.: 10,188,299
`
`
`
`Atty. Dkt. No.: OMSC0117IPR1
`
`Thomas A. Lewry (Reg. No. 30,770)
`John S. LeRoy (Reg. No. 48,158)
`Robert C. J. Tuttle (Reg. No. 27,962)
`John M. Halan (Reg. No. 35,534)
`Christopher C. Smith (Reg. No. 59,669)
`Andrew B. Turner (Reg. No. 63,121)
`BROOKS KUSHMAN P.C.
`1000 Town Center, Twenty-Second Floor
`Southfield, Michigan 48075
`Telephone: (248) 358-4400
`
`Attorneys for Omni MedSci, Inc.
`
`6
`
`
`
`Case No.: IPR2020-00175
`Patent No.: 10,188,299
`
`
`
`Atty. Dkt. No.: OMSC0117IPR1
`
`Certificate of Service
`
`The undersigned certifies that on May 28, 2020, a complete and entire copy of
`
`PATENT OWNER’S SUR-REPLY REGARDING 35 U.S.C. § 325(d), was served
`
`via electronic mail by
`
`serving
`
`the correspondence email address of
`
`IPRnotices@sidley.com, which delivers to the following lead and back-up counsel:
`
`LEAD COUNSEL
`Jeffrey P. Kushan
`(Reg. No. 43,401)
`SIDLEY AUSTIN LLP
`1501 K Street NW
`Washington, DC 20005
`(202) 736-8914
`
`BACK-UP COUNSEL
`Ching-Lee Fukuda (Reg. No. 44,334)
`Sidley Austin LLP
`787 Seventh Avenue
`New York, NY 10019
`
`Thomas A. Broughan III (Reg. No. 66,001)
`Sidley Austin LLP
`1501 K Street NW
`Washington, DC 20005
`
`Sharon Lee (pro hac vice)
`
`Respectfully submitted,
`
` /Thomas A. Lewry/
`
`
`Thomas A. Lewry (Reg. No. 30,770)
`John S. LeRoy (Reg. No. 48,158)
`Robert C. J. Tuttle (Reg. No. 27,962)
`John M. Halan (Reg. No. 35,534)
`Christopher C. Smith (Reg. No. 59,669)
`Andrew B. Turner (Reg. No. 63,121)
`BROOKS KUSHMAN P.C.
`1000 Town Center, Twenty-Second Floor
`Southfield, Michigan 48075
`Telephone: (248) 358-4400
`
`Attorneys for Omni MedSci, Inc.
`
`7
`
`
`
`Case No.: IPR2020-00175
`Patent No.: 10,188,299
`
`
`
`Atty. Dkt. No.: OMSC0117IPR1
`
`Certificate of Compliance Pursuant to 37 C.F.R. § 42.24
`
`
`
`
`This paper complies with the type-volume limitation of 37 C.F.R. § 42.24.
`
`The paper contains 1,141 words, excluding the parts of the paper exempted by
`
`§42.24(a).
`
`This paper also complies with the typeface requirements of 37 C.F.R.
`
`§ 42.6(a)(ii) and the type style requirements of § 42.6(a)(iii)&(iv).
`
`
`Dated: May 28, 2020
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
` /Thomas A. Lewry/
`
`
`Thomas A. Lewry (Reg. No. 30,770)
`John S. LeRoy (Reg. No. 48,158)
`Robert C. J. Tuttle (Reg. No. 27,962)
`John M. Halan (Reg. No. 35,534)
`Christopher C. Smith (Reg. No. 59,669)
`Andrew B. Turner (Reg. No. 63,121)
`BROOKS KUSHMAN P.C.
`1000 Town Center, Twenty-Second Floor
`Southfield, Michigan 48075
`Telephone: (248) 358-4400
`
`Attorneys for Omni MedSci, Inc.
`
`8
`
`